|1.||Pasqualini, Jorge R: 3 articles (12/2009 - 10/2007)|
|2.||Pasqualini, Jorge Raul: 1 article (02/2009)|
|3.||von Holst, Thomas: 1 article (12/2002)|
|4.||Winkler, Ulrich: 1 article (12/2002)|
|5.||Keil, Dieter: 1 article (12/2002)|
|6.||Lang, Eva: 1 article (12/2002)|
|7.||Ebert, C: 1 article (12/2001)|
|8.||Chetrite, G S: 1 article (12/2001)|
|9.||Pasqualini, J R: 1 article (12/2001)|
|10.||Gomez Perez, F J: 1 article (02/2001)|
|1.||Mood Disorders (Mood Disorder)
|2.||Vertigo (Positional Vertigo)
|3.||Breast Neoplasms (Breast Cancer)
07/01/1999 - "In the present study, we explored the effect of the progestin medrogestone on the sulfatase and sulfotransferase activities in the hormone-dependent MCF-7 and T-47D human breast cancer cell lines. "
07/01/1999 - "In conclusion, the inhibitory effect provoked by medrogestone on the enzyme involved in the biosynthesis of E2 (sulfatase pathway) in estrogen-dependent breast cancer, as well as the stimulatory effect on the formation of the inactive ES, support a probable anti-proliferative effect of this progestin in breast tissue. "
07/01/1999 - "Control of sulfatase and sulfotransferase activities by medrogestone in the hormone-dependent MCF-7 and T-47D human breast cancer cell lines."
09/01/1972 - "Disseminated breast cancer: evaluation of hormonal therapy utilizing stilbestrol and medrogestone (AY-62022) singly and in combination."
01/01/1999 - "It is concluded that the inhibition provoked by Medrogestone on the reductive 17beta-HSD activity involved in the local biosynthesis of the biologically active estrogen estradiol, may constitute a new therapeutic approach for the treatment of breast cancer."
09/01/1996 - "Four medrogestone-treated patients dropped out due to unscheduled bleeding. "
09/01/1996 - "A low dose of medrogestone added to transdermal estradiol induced incomplete transformation of endometrium and oligo-amenorrhea more frequently than MPA, but it increased the chances of irregular bleeding. "
09/01/1996 - "We evaluated bleeding pattern and endometrium following the administration of two of the most common types of progestogens used in hormone replacement therapy, medroxyprogesterone acetate (MPA) and medrogestone acetate. "
12/10/2002 - "Bleeding patterns in peri and postmenopausal women taking a continuous combined regimen of estradiol with norethisterone acetate or a conventional sequential regimen of conjugated equine estrogens with medrogestone."
12/10/2002 - "The aim of this study was to compare the incidence of women presenting irregular bleeding episodes following 9 months of treatment with a low dose continuous combined hormone replacement therapy consisting of estradiol (E(2)) and norethisterone acetate (NETA) versus a sequential hormone replacement therapy consisting of conjugated equine estrogens (CEE) and medrogestone (MG). "
|5.||Uterine Hemorrhage (Uterine Bleeding)
03/01/1993 - "In this study menopausal symptoms, endometrial histology, uterine bleeding pattern, plasma lipid concentrations, bone mineral loss, body weight and blood pressure have been evaluated in postmenopausal women who received continuous conjugated equine estrogens and medrogestone over a 1 year treatment period. "
|1.||Conjugated (USP) Estrogens (Premarin)
|6.||3 (or 17)-beta-hydroxysteroid dehydrogenase
|7.||norethindrone acetate (Norlutate)
|1.||Hormone Replacement Therapy (Therapy, Hormone Replacement)